
Medications such as Ozempic and Wegovy have become increasingly popular for managing diabetes and weight loss. However, recent regulatory reviews in Europe and the United States have identified a potential association between semaglutide, the active ingredient in these medications, and a rare but serious eye condition called non-arteritic anterior ischemic optic neuropathy (NAION).
Sometimes described as a "stroke of the optic nerve," NAION occurs when blood flow to the optic nerve is reduced, depriving the nerve of oxygen and nutrients. It typically causes sudden, painless vision loss in one eye, which can be permanent. Unfortunately, there is currently no reliably effective treatment to restore vision lost from this condition.
European regulators recognized NAION as a very rare potential side effect of semaglutide in 2025, estimating that it could affect up to 1 in 10,000 users. The FDA has also reviewed clinical trial data involving more than 134,000 participants and identified a potential association.
The overall risk is low but these medications are prescribed to millions of people. Importantly, research has not yet established a definitive cause-and-effect relationship between GLP-1 medications and NAION.
Diabetes is an established risk factor for NAION and can independently affect vision through diabetic retinopathy, which damages the blood vessels of the retina. This can make it difficult to distinguish an underlying diabetic eye complication from a possible medication-associated problem.
Patients taking Ozempic, Wegovy, or other semaglutide medications should understand the potential warning signs of NAION. These include:
A comprehensive eye examination can help document existing retinal disease, evaluate optic nerve health, and establish a baseline for future comparisons. Patients with diabetes should continue their regular diabetic eye examinations.
Patients should also discuss their individual risk factors and any concerns with their prescribing physician. They should not discontinue prescribed medication without medical guidance.
GLP-1 medications provide important benefits for many patients managing diabetes and weight. However, their potential association with rare but serious eye complications highlights the importance of communication between patients, prescribing physicians, and eye care professionals.
At Tacoma Eye, we believe that understanding how systemic medications can affect vision is an important part of protecting long-term eye health. While the article's author advocates comprehensive eye examinations when starting GLP-1 medications. This is the author's recommendation, not necessarily an established universal FDA or the American Academy of Optometry or the American Optometric association.